Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
Completed · Phase 1
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying the side effects and best dose of a monoclonal antibody in treating patients with stage IV melanoma.
Key facts
- Study ID
- NCT00658892
- Run by
- Mayo Clinic
- People needed
- 7
- Starts
- 2008-04-08
- Expected to finish
- 2012-05-22
- Last updated by the study team
- 2017-05-25
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.